Drug Can Starve Cancer Stem Cells

Cells, including cancerous ones, cannot thrive without energy production. An obscure drug may fight off cancer by preventing energy production within cancer stem cells, essentially switching the cells off, according to a study published by Aging.

The drug, called diphenyleneiodonium (DPL), can inhibit the production of vitamins that feed cancer cells, causing the cells to starve.

“Our observation is that DPI is selectively attacking the cancer stem cells, by effectively creating a vitamin deficiency,” said researcher Michael Lisanti, MD, PhD. “In other words, by turning off energy production in cancer stem cells, we are creating a process of hibernation.”

DPI stops the reproduction of cancer cells by cutting off their energy source, according to the study. The drug does this without creating the toxic adverse effects that are common with traditional chemotherapies, according to the study.

The authors found that DPI had this effect on cancer stem cells, preventing the creation of more cancer cells. When added to a mixed population of cells, DPI sent stem cells into hibernation, according to the study; however, the drug did not fight against “bulk” cancer cells, which do not typically initiate tumor growth within patients, according to the authors.

DPI was observed to inhibit more than 90 protein enzymes from being converted into cellular energy in the mitochondria, according to the study. The lack of energy production deprives cancer cells of vitamin B-12 and riboflavin, which shuts the stem cell down and prevents growth.

“It’s extraordinary; the cells just sit there as if in a state of suspended animation,” Dr Lisanti said.

The treatment also works by weakening the cell and making it vulnerable to other drugs used to fight cancer, according to Dr Lisanti.

“The beauty of this is that DPI makes the cancer stem cells metabolically-inflexible, so they will be highly susceptible to a many other drugs,” he said.

DPI is groundbreaking because it does not create the free radicals that lead to the significant adverse events associated with chemotherapy, according to the authors.

The researchers have previously searched for new and innovative non-toxic treatments for cancer and have discovered other treatments that can kill cancer stem cells, such as the effective combination of vitamin C and antibiotics.

The authors are calling DPI treatment a new form of chemotherapy: mitoflavoscins.

“In terms of chemotherapies for cancer, we clearly need something better that what we have at present, and this is hopefully the beginning of an alternative approach to halting cancer stem cells,” said co-author Federica Sotgia, PhD.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Top news of the week from Specialty Pharmacy Times.
The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.
Top news of the day across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.